Nuformix PLC (NFXN)

London
1.4601
-0.0149(-1.01%)
  • Volume:
    3,020,872
  • Bid/Ask:
    1.4500/1.5000
  • Day's Range:
    1.4560 - 1.4850

NFXN Overview

Prev. Close
1.475
Day's Range
1.456-1.485
Revenue
200K
Open
1.485
52 wk Range
1.45-6.3999
EPS
0
Volume
3,020,872
Market Cap
8.64M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
5,139,756
P/E Ratio
-
Beta
0.95
1-Year Change
-60%
Shares Outstanding
591,609,368
Next Earnings Date
-
What is your sentiment on Nuformix PLC?
or
Market is currently closed. Voting is open during market hours.

Nuformix PLC News

  • Nuformix CEO to step down
    • ByProactiveinvestors-

    Nuformix PLC (LON:NFX) said its chief executive Anne Brindley has decided to step down from her role. The pharmaceutical development firm said Brindley will continue in her current...

  • Nuformix says drug pipeline is 'building momentum'
    • ByProactiveinvestors-

    Nuformix PLC (LON:NFX) chief executive Anne Brindley said fundraises in the past year have allowed the pharmaceutical company to develop its pipeline of repurposed drug assets and...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Nuformix PLC Company Profile

Nuformix PLC Company Profile

Employees
3

Nuformix plc, a pharmaceutical development company, develops drugs using cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP004, which is under the pre-clinical stage for the treatment of multiple forms of fibrosis in various human tissues. It has an agreement with VistaGen Therapeutics, Inc. to develop co-crystal-based formulations of AV-101 for the treatment of various central nervous system conditions. The company also has an option agreement with Oxilio Ltd. to provide consultancy services for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.

Read More
  • Strong buy...so much positive news. due q1
    4
    • What news? Never came...
      1
  • Nice to see a positive rns onwards and upwards
    1
    • much more to come. Hold for next waves. sales news and other milestones such as NX0002
      0
      • This could seriously do multiples of current SP.
        2
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.